VKTX heads into Q1 earnings results with a focus on pipeline updates, as it expects no revenues and continued losses amid key ...

Koyfin estimates point to a Q1 GAAP loss per share of $1.03, widening from a loss of $0.4 a year earlier. ・Revenue is expected to remain zero as the company continues to operate in the clinical ...

Viking Therapeutics (VKTX) has recently drawn investor attention after its shares closed at US$35.20, with return figures across the past week, month and past 3 months providing a fresh snapshot of ...

In the latest close session, Viking Therapeutics, Inc. (VKTX) was down 4.23% at $32.80. The stock trailed the S&P 500, which registered a daily loss of 0.41%. Meanwhile, the Dow experienced a drop of ...

Viking's candidate is part of the GLP-1 class of drugs, which interact with hormonal pathways controlling appetite and blood ...

Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading this week, for the December 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the positions showed up on publicly ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in General Motors Co (Symbol: GM), where a total of 73,915 contracts have traded so far, ...

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 12, Michael Ulz from Morgan Stanley reduced his price target on Viking ...

Viking posted a loss of $1.38 per share, worse than the 89 cent loss analysts were expecting. Last quarter, the company only missed on EPS by 13 cents, according to Benzinga Pro. The miss was driven ...